The medical takeaway is simple: retatrutide is not just another celebrity weight-loss trend. It is part of a larger movement toward more powerful incretin-based therapies that may change how obesity, metabolic disease, and body composition are treated
Association of alcohol drinking with incident type 2 diabetes and pre-diabetes: The Guangzhou Biobank Cohort Study
This years 2026 American Society of Clinical Oncology (ASCO) Annual Meeting revealed two such studies
Further studies should now focus on non-inferiority studies comparing these new oral molecules against currently recommended injectable GLP-1 RAs to have a clear comparison between these families of medications
The Science Behind Digbi GLP-Fit() This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs
This broader mechanism may explain why retatrutide has shown greater weight loss potential in clinical trials
